Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237456 | 0.90 | LMNA (0.41) | ALDH1A1HSD17B10KDM4EHPGDTHRB | |
| SCHEMBL7235505 | 0.90 | KDM4E (0.46) | ALDH1A1HSD17B10KDM4EHPGDTHRB | |
| SCHEMBL9786124 | 0.90 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6603300 | 0.88 | LMNA (0.55) | ALDH1A1HSD17B10KDM4EHPGDTHRB | |
| SCHEMBL6603303 | 0.83 | LMNA (0.44) | ALDH1A1HSD17B10KDM4EHPGDTHRB | |
| SCHEMBL7234823 | 0.82 | KMT2A (0.47) | ALDH1A1HSD17B10KDM4EHPGDTHRB | |
| SCHEMBL8941943 | 0.82 | KDM4E (0.43) | ALDH1A1HSD17B10KDM4EHPGDKMT2A | |
| SCHEMBL8942157 | 0.82 | KDM4E (0.44) | ALDH1A1HSD17B10KDM4EHPGDKMT2A | |
| Choline SCHEMBL7237451 | 0.81 | LMNA (0.40) | ALDH1A1HSD17B10KDM4EHPGDTHRB | |
| SCHEMBL8941980 | 0.81 | KDM4E (0.42) | ALDH1A1HSD17B10KDM4EHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548506-B2 | 1-substituted,3-carboxy,7-fluoro,8-disubstituted amino-1,4-dihydrobenzo(b)(1,8)naphthyridin-4-ones; Useful as antimicrobial agents; topical antibiotic for wounds | AVENTIS PHARMA S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-20020037891-A1 | Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them | AVENTIS PHARMA S.A. (FR) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037891-A1 | Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them | ABCB11, NDUFA9, NDUFC1 | ALDH1A1 672/4885HSD17B10 1596/4885KDM4E 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.